139 related articles for article (PubMed ID: 21122936)
1. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Esteghamati A; Alamdari A; Zandieh A; Elahi S; Khalilzadeh O; Nakhjavani M; Meysamie A
Diabetes Res Clin Pract; 2011 Feb; 91(2):154-8. PubMed ID: 21122936
[TBL] [Abstract][Full Text] [Related]
2. Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Mohammadi S; Hosseinzadeh-Attar MJ; Hosseinnezhad A; Hosseini SH; Eshraghian MR; Nezhad MK; Rahmani M; Karimi M
Diabetes Metab Syndr; 2011; 5(2):71-5. PubMed ID: 22813406
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome].
Wang Y; Yu P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 34(1):72-5. PubMed ID: 19197132
[TBL] [Abstract][Full Text] [Related]
4. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Alghasham AA; Barakat YA
Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
[TBL] [Abstract][Full Text] [Related]
5. Adipokines and cardiometabolic function: How are they interlinked?
Schutte AE; Huisman HW; Schutte R; van Rooyen JM; Malan L; Fourie CM; Malan NT
Regul Pept; 2010 Sep; 164(2-3):133-8. PubMed ID: 20615436
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin and leptin in Afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes.
Deloumeaux J; Maachi M; Sow-Goerger MT; Lamaury I; Velayoudom FL; Cheret A; Batard ML; Muller P; Bastard JP; Chene G; Capeau J; Foucan L
Diabetes Metab; 2011 Apr; 37(2):98-104. PubMed ID: 21126901
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters.
Dalamaga M; Karmaniolas K; Papadavid E; Pelekanos N; Sotiropoulos G; Lekka A
Menopause; 2011 Nov; 18(11):1198-204. PubMed ID: 21712732
[TBL] [Abstract][Full Text] [Related]
9. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.
Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W
Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460
[TBL] [Abstract][Full Text] [Related]
10. Association of leptin with insulin resistance, body composition, and lipid parameters in postmenopausal women and men in type 2 diabetes mellitus.
Gulturk S; Cetin A; Erdal S
Saudi Med J; 2008 Jun; 29(6):813-20. PubMed ID: 18521457
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 6, adiponectin, leptin, and insulin resistance in nonobese Japanese type 2 diabetic patients.
Taniguchi A; Fukushima M; Ohya M; Nakai Y; Yoshii S; Nagasaka S; Matsumoto K; Taki Y; Kuroe A; Nishimura F; Seino Y
Metabolism; 2006 Feb; 55(2):258-62. PubMed ID: 16423635
[TBL] [Abstract][Full Text] [Related]
12. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
[TBL] [Abstract][Full Text] [Related]
13. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
Caixàs A; Tirado R; Vendrell J; Gallart L; Megía A; Simón I; Llauradó G; González-Clemente JM; Giménez-Palop O
Clin Endocrinol (Oxf); 2009 Nov; 71(5):733-8. PubMed ID: 19222486
[TBL] [Abstract][Full Text] [Related]
14. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol.
Jin H; Jiang B; Tang J; Lu W; Wang W; Zhou L; Shang W; Li F; Ma Q; Yang Y; Chen M
Diabetes Res Clin Pract; 2008 Mar; 79(3):412-8. PubMed ID: 18241953
[TBL] [Abstract][Full Text] [Related]
15. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus.
Akbarzadeh S; Nabipour I; Jafari SM; Movahed A; Motamed N; Assadi M; Hajian N
Diabetes Res Clin Pract; 2012 Jan; 95(1):132-8. PubMed ID: 22024288
[TBL] [Abstract][Full Text] [Related]
16. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity.
Hasegawa G; Ohta M; Ichida Y; Obayashi H; Shigeta M; Yamasaki M; Fukui M; Yoshikawa T; Nakamura N
Acta Diabetol; 2005 Jun; 42(2):104-9. PubMed ID: 15944845
[TBL] [Abstract][Full Text] [Related]
17. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Pfützner A; Marx N; Walcher D; Löbig M; Seidel D; Forst T
Clin Lab; 2008; 54(7-8):237-41. PubMed ID: 18942491
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin and visfatin concentrations in children treated with valproic acid.
Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Ernst B; Hoppichler F; Karall D; Ebenbichler CF; Rostasy K; Luef G
Epilepsia; 2008 Feb; 49(2):353-7. PubMed ID: 18070089
[TBL] [Abstract][Full Text] [Related]
19. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men.
Peng XD; Xie H; Zhao Q; Wu XP; Sun ZQ; Liao EY
Clin Chim Acta; 2008 Jan; 387(1-2):31-5. PubMed ID: 17884030
[TBL] [Abstract][Full Text] [Related]
20. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Wang P; Bai C; Xu QY; Xu TY; Su DF; Sassard J; Miao CY
Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):894-9. PubMed ID: 20456420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
